

Press release
March 3, 2025



Diagonal Bio applies for change of marketplace to NGM Nordic SME

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today announces that the Company – in order to be able to reallocate costs – has decided to apply for listing on NGM Nordic SME ("NGM"). The decision is based on the evaluation that the move from Nasdaq First North Growth Market to NGM will result in lower costs and thus possibilities for Diagonal Bio to allocate more of the available capital to marketing and sales.

Diagonal Bio has been listed on Nasdaq First North Growth Market since July 2021. The objective is to complete the move during March 2025.

For additional information about Diagonal Bio, please contact:

Karin Wehlin, CEO
Phone: +46 70 305 24 88
E-mail: kw@diagonalbio.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se

About Diagonal Bio

Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPLify®.